ClinicalTrials.gg
CompletedNCT01241240Updated Sep 10, 2014Results posted

Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

A Phase 3 interventional study of bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy) and Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution in Glaucoma, Open-Angle and Ocular Hypertension, sponsored by Allergan. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-10.

Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing bimatoprost in Glaucoma, Open-Angle — 2 open to participants now, 2 under way, 1 of them phase 3. Bimatoprost · Glaucoma, Open-Angle.

Enrollment
13th of 29
192 · median 169
Started
2011
with 5 others
Phase 3
9 of 29
1 open now
Registered
5th of 29
by date
Lead sponsor
17 of 29
Allergan

Among the 29 studies testing bimatoprost in Glaucoma, Open-Angle, this one is the 13th largest by enrollment, is one of 6 that started in 2011, is one of 9 in phase 3, and was the 5th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

2 of the 29 studies testing bimatoprost in Glaucoma, Open-Angle are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About bimatoprost

Bimatoprost: first FDA approval 2001 (LUMIGAN), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing bimatoprost in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

This study will evaluate the safety and efficacy of Triple Combination Therapy compared with Fixed Combination brimonidine tartrate/timolol ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension.

03

Conditions studied

  • Glaucoma, Open-Angle
  • Ocular Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ocular hypertension or primary open-angle glaucoma in each eye
  • Requires treatment with IOP-lowering medication in both eyes

Exclusion criteria

Exclusion Criteria:

  • Required chronic use of ocular medications during the study other than study medication
  • Use of any within 30 days
  • History of any prior eye surgery, except for uncomplicated eye surgery performed more than 6 months before the Screening visit
  • Anticipated wearing of contact lenses during the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
192 participants (actual)

Study arms

  • Experimental
    Triple Combination Therapy

    Triple Combination Therapy with bimatoprost/brimonidine tartrate/timolol ophthalmic solution. One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.

    Drug: bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)

  • Active comparator
    Combigan®

    Fixed Combination brimonidine tartrate/timolol ophthalmic solution (Combigan®). One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for 12 weeks.

    Drug: Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution

Interventions

  • Drugbimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)

    Drug pages: Bimatoprost · Brimonidine · Timolol

    One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.

  • DrugFixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution

    One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for 12 weeks.

    Also known as: COMBIGAN®

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) at Week 12

    IOP is a measurement of the fluid pressure inside the eye. For each eye, the IOP was either the average of 2 measurements, or, if a third measurement was required, the median of the 3 measurements. The worse eye was determined based on the IOP results at Baseline. The mean worse eye IOP was the average of the IOP measurements of the worse eye at hours 0 and 2 at week 12. A negative change from Baseline indicated improvement.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Change From Baseline in Mean Worse Eye IOP

    IOP is a measurement of the fluid pressure inside the eye. For each eye, the IOP was either the average of 2 measurements, or, if a third measurement was required, the median of the 3 measurements. The worse eye was determined based on the IOP results at Baseline. The mean worse eye IOP was the average of the IOP measurements of the worse eye at hours 0 and 2 at each visit. A negative change from Baseline indicated improvement.

    Time frame: Baseline, Weeks 1, 2, 4 and 8

  2. Mean Worse Eye IOP

    IOP is a measurement of the fluid pressure inside the eye. For each eye, the IOP was either the average of 2 measurements, or, if a third measurement was required, the median of the 3 measurements. The worse eye was determined based on the IOP results at Baseline. The mean worse eye IOP was the average of the IOP measurements of the worse eye at hours 0 and 2 at each time-point.

    Time frame: Weeks 1, 2, 4, 8 and 12

07

Results

Posted Sep 10, 2014

Participant flow

Participant flow — Overall Study
MilestoneTriple Combination TherapyCombigan®
Started9498
Completed8689
Not completed89
Withdrew: Adverse event54
Withdrew: Lost to follow-up24
Withdrew: Personal reasons11

Outcome measures

PrimaryChange From Baseline in Mean Worse Eye Intraocular Pressure (IOP) at Week 12

IOP is a measurement of the fluid pressure inside the eye. For each eye, the IOP was either the average of 2 measurements, or, if a third measurement was required, the median of the 3 measurements. The worse eye was determined based on the IOP results at Baseline. The mean worse eye IOP was the average of the IOP measurements of the worse eye at hours 0 and 2 at week 12. A negative change from Baseline indicated improvement.

Time frame:
Baseline, Week 12
Reported as:
Mean · mmHg
Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) at Week 12
mmHgTriple Combination TherapyCombigan®
Baseline (n=93,95)24.62 ± 2.47525.12 ± 2.178
Change from Baseline at Week 12 (n=93,94)-10.03 ± 2.661-9.18 ± 2.566
SecondaryChange From Baseline in Mean Worse Eye IOP

IOP is a measurement of the fluid pressure inside the eye. For each eye, the IOP was either the average of 2 measurements, or, if a third measurement was required, the median of the 3 measurements. The worse eye was determined based on the IOP results at Baseline. The mean worse eye IOP was the average of the IOP measurements of the worse eye at hours 0 and 2 at each visit. A negative change from Baseline indicated improvement.

Time frame:
Baseline, Weeks 1, 2, 4 and 8
Reported as:
Mean · mmHg
Change From Baseline in Mean Worse Eye IOP
mmHgTriple Combination TherapyCombigan®
Baseline (n=93,95)24.62 ± 2.47525.12 ± 2.178
Change from Baseline at Week 1 (n=91,89)-10.18 ± 3.149-8.90 ± 3.044
Change from Baseline at Week 2 (n=88,93)-10.40 ± 2.802-9.06 ± 2.925
Change from Baseline at Week 4 (n=86,90)-10.06 ± 2.793-9.21 ± 2.306
Change from Baseline at Week 8 (n=88,89)-9.77 ± 2.852-9.02 ± 2.869
SecondaryMean Worse Eye IOP

IOP is a measurement of the fluid pressure inside the eye. For each eye, the IOP was either the average of 2 measurements, or, if a third measurement was required, the median of the 3 measurements. The worse eye was determined based on the IOP results at Baseline. The mean worse eye IOP was the average of the IOP measurements of the worse eye at hours 0 and 2 at each time-point.

Time frame:
Weeks 1, 2, 4, 8 and 12
Reported as:
Mean · mmHg
Mean Worse Eye IOP
mmHgTriple Combination TherapyCombigan®
Week 1 (n=91,90)14.43 ± 2.78516.23 ± 2.968
Week 2 (n=88,95)14.05 ± 2.63416.08 ± 2.726
Week 4 (n=86,92)14.38 ± 2.58715.96 ± 2.705
Week 8 (n=88,91)14.68 ± 2.70916.11 ± 2.935
Week 12 (n=86,88)14.43 ± 2.34415.92 ± 2.867

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Triple Combination Therapy—3/93 (3.2%)57/93 (61.3%)
Combigan®—0/98 (0%)25/98 (25.5%)
Most frequent serious events
Most frequent serious events
EventTriple Combination TherapyCombigan®
BradycardiaCardiac disorders1/930/98
PneumothoraxRespiratory, thoracic and mediastinal disorders1/930/98
PyomyositisInfections and infestations1/930/98
Pituitary tumourNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/930/98
Most frequent other events
Most frequent other events
EventTriple Combination TherapyCombigan®
Conjunctival hyperaemiaEye disorders22/934/98
Eye irritationEye disorders13/934/98
Dry eyeEye disorders10/932/98
SomnolenceNervous system disorders5/938/98
Eye pruritusEye disorders6/932/98
Visual field defectNervous system disorders5/935/98

Baseline characteristics

Age, Customized
Age, Customized(Participants)Triple Combination TherapyCombigan®Total
≤65 years6774141
>65 years272451
Sex: Female, Male
Sex: Female, Male(Participants)Triple Combination TherapyCombigan®Total
Female7873151
Male162541
08

Study locations

2 sites
  • Bogotá, Colombia
  • Mexico City, Mexico
09

References and documents

Publications

  • Hartleben C, Parra JC, Batoosingh A, Bernstein P, Goodkin M. A Masked, Randomized, Phase 3 Comparison of Triple Fixed-Combination Bimatoprost/Brimonidine/Timolol versus Fixed-Combination Brimonidine/Timolol for Lowering Intraocular Pressure. J Ophthalmol. 2017;2017:4586763. doi: 10.1155/2017/4586763. Epub 2017 Sep 19. PubMed 29057117 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2014, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2010
First posted
Nov 16, 2010
Start
Mar 2011
Primary completionActual
Sep 2013
CompletionActual
Sep 2013
Results first posted
Sep 10, 2014
Last update
Sep 10, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01241240
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Nov 16, 2010
Start date
Mar 2011
Primary completion
Sep 2013
Completion
Sep 2013
Results posted
Sep 10, 2014
Last update
Sep 10, 2014

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bimatoprost · Brimonidine · Timolol

Start the discussion